Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease, with a particular emphasis on chronic hepatitis B virus (cHBV) infection. The ABUS news feed highlights company announcements on clinical data, corporate strategy and intellectual property developments that shape the outlook for its pipeline and technology.
Investors and observers following ABUS news can find regular updates on imdusiran (AB-729), Arbutus’ RNAi therapeutic designed to reduce hepatitis B viral proteins and antigens including HBsAg. News items include results from Phase 1 and Phase 2a trials, such as reports of patients achieving what the company describes as functional cure, analyses of HBsAg and HBV DNA reductions, and presentations at major liver disease conferences including the European Association for the Study of the Liver (EASL) Congress and the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting.
The ABUS news stream also covers developments related to AB-101, the company’s oral PD-L1 inhibitor candidate. Releases describe safety, tolerability and pharmacodynamic findings from the ongoing Phase 1a/1b trial in healthy volunteers and cHBV patients, including data on PD-L1 receptor occupancy and the absence of AB-101-related serious adverse events reported to date.
Another recurring theme in Arbutus news is its LNP intellectual property. Joint announcements with Genevant Sciences and company updates detail U.S. and international patent infringement actions against Moderna and Pfizer/BioNTech concerning the use of LNP technology in COVID-19 vaccines. Corporate news also includes board and executive changes, restructuring actions, and strategic decisions such as reacquiring Greater China rights to imdusiran and forming a Scientific Advisory Board of cHBV experts.
For those tracking ABUS stock and the company’s progress in hepatitis B and LNP technology, this news page provides a centralized view of clinical milestones, litigation updates and corporate developments as disclosed by Arbutus in its press releases.
Arbutus Biopharma (Nasdaq: ABUS) will release its first quarter 2022 financial results on May 5, 2022, at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the conference call via the company's website or through specific dial-in numbers provided. The company focuses on developing novel therapeutics targeting viral diseases, including Hepatitis B and coronaviruses, with ongoing phase 2 clinical trials for its lead compound, AB-729, aimed at providing a functional cure for HBV.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its Q4 and year-end 2021 results, highlighting a net loss of $88.4 million, or $0.83 per share. The company has $191 million in cash and investments, compared to $123 million in 2020. Notably, it anticipates key clinical trial data for its HBV therapies later this year. Arbutus plans to advance several compounds, including AB-101 and AB-161, into IND-enabling studies and filed a patent infringement lawsuit against Moderna regarding its COVID-19 vaccine. The company expects a cash burn of $90-$95 million in 2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) and Genevant Sciences have filed a lawsuit against Moderna (Nasdaq: MRNA) for patent infringement regarding their mRNA COVID-19 vaccine, MRNA-1273. The patents in question cover nucleic acid-lipid particles and related technologies. Arbutus CEO, William Collier, emphasized they are not seeking to halt vaccine sales but are pursuing compensation for their patented technology, crucial for vaccine success. Additionally, a previous court ruling upheld the validity of the patents involved, posing potential ongoing challenges for Moderna.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it will release its fourth quarter and year-end 2021 financial results on March 3, 2022, at 7:30 a.m. ET, followed by a conference call at 8:45 a.m. ET. The company focuses on developing therapeutics for viral diseases, including ongoing clinical trials for its lead compound, AB-729, targeting Hepatitis B virus. A live webcast will be available on Arbutus' investor website, and an archived version will be accessible after the event.
Arbutus Biopharma Corporation (NASDAQ: ABUS) announced its 2022 objectives and financial status, highlighting anticipated clinical data readouts for its HBV candidates AB-729 and AB-836. The company completed IND-enabling studies for oral therapies AB-101 and AB-161. Significant cash reserves amounting to $191 million provide a runway into Q2 2024. CEO William Collier emphasized the importance of this year for HBV research, with multiple clinical trials underway and results expected to further support Phase 2b development.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the H.C. Wainwright Bioconnect Virtual Conference from January 10-13, 2022. The virtual fireside chat will feature key executives including William Collier (President and CEO) and Dr. Michael Sofia (Chief Scientific Officer). The chat will start at 7:00 am EST on January 10, 2022, with a webcast available on Arbutus' website. Arbutus is focused on developing therapies for chronic hepatitis B and coronaviruses, including COVID-19.
On December 14, 2021, Antios Therapeutics and Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the dosing of the first patient in a Phase 2a clinical trial evaluating a triple combination treatment for chronic hepatitis B virus (HBV) infection. The study involves 40 patients and aims to assess the efficacy of Antios' ATI-2173 and Arbutus' AB-729 with tenofovir disoproxil fumarate (TDF). This combination therapy seeks to achieve a functional cure for HBV by reducing viral replication and antigens. Both companies express optimism regarding the therapeutic potential of this innovative combination.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has formed a strategic partnership with Qilu Pharmaceutical for the development of AB-729, an RNA interference therapeutic aimed at treating hepatitis B in China, Hong Kong, Macau, and Taiwan. Arbutus will receive an upfront payment of $40 million, with potential milestone payments of up to $245 million and double-digit royalties on sales. Qilu will handle all development and commercialization efforts, marking a significant opportunity for Arbutus to reach a large patient population in a lucrative market.
Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the discovery of small molecules that inhibit the SARS-CoV-2 nsp5 main protease, a significant target for COVID-19 treatment. This achievement marks a milestone in collaboration with X-Chem and Proteros, obtaining a worldwide exclusive license for these compounds. The parties aim to expedite the development of pan-coronavirus therapies. This discovery occurred just six months after initiating their agreement, highlighting Arbutus's commitment to effective antiviral treatments against COVID-19 and future outbreaks.
Arbutus Biopharma (Nasdaq: ABUS) announced promising preliminary data from its ongoing Phase 1a/1b trial of the capsid inhibitor AB-836, aimed at treating chronic hepatitis B virus (cHBV) infection. The trial indicates that AB-836 is generally safe and well-tolerated, showing robust antiviral activity with a significant mean drop in HBV DNA levels. No serious adverse events were reported among healthy subjects or cHBV patients. The study continues, with 16 cHBV patients dosed in Part 3, and more data is expected to be presented in 2022.